Gilead Sciences (GILD) Q4 Revenue Tops Views, Offers Guidance

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.78, $0.11 better than the analyst estimate of $1.67. Revenue for the quarter came in at $5.9 billion versus the consensus estimate of $5.74 billion.

GUIDANCE:

Gilead Sciences sees FY2018 revenue of $20-21 billion, versus the consensus of $21.97 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30